1230 US Highway 11
Gouverneur, NY 13642
Phone: 1-877-635-9545
Prior Authorization Fax: 1-844-712-8129

Stelara® Prior Authorization Request Form (Page 1 of 2)

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
❑ Check if requesting **brand**	Directions for Use:	
❑ Check if request is for **continuation of therapy**		

Clinical Information (required)

Select the diagnosis below:

❑ Active psoriatic arthritis
❑ Moderate to severe plaque psoriasis
❑ Moderately to severely active Crohn's disease
❑ Other diagnosis:_____ICD-10 Code(s): _____

Clinical Information:

Please document the patient's weight:_____lbs/kg

Select if Stelara is prescribed by or in consultation with one of the following specialists:
- ❑ Dermatologist
- ❑ Gastroenterologist
- ❑ Rheumatologist

Is the patient receiving Stelara in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]? ❑ **Yes** ❑ **No**

For moderately to severely active Crohn's disease, also answer the following:

Does the patient have history of failure, contraindication, or intolerance to at least one tumor necrosis factor (TNF) blocker [e.g., Remicade/Inflectra (infliximab), Humira (adalimumab), Cimzia (certolizumab pegol)]? ❑ **Yes** ❑ **No**

Does the patient have history of failure, contraindication, or intolerance to treatment with at least one immunomodulator or corticosteroids [e.g., Purinethol (6-mercaptopurine), Imuran (azathioprine), Sandimmune (cyclosporine A), Prograf (tacrolimus), MTX (methotrexate)]? ❑ **Yes** ❑ **No**

Is this for continuation of prior Stelara therapy? ❑ **Yes** ❑ **No**

For intravenous (IV) Stelara, answer the following:

Is Stelara to be administered as an intravenous induction dose? ❑ **Yes** ❑ **No**

Select the induction dosing that will be used in accordance with the United States Food and Drug Administration approved labeled dosing for Crohn's disease:
- ❑ 260 mg for patients weighing 55 kg or less
- ❑ 390 mg for patients weighing more than 55 kg to 85 kg
- ❑ 520 mg for patients weighing more than 85 kg

1230 US Highway 11
Gouverneur, NY 13642
Phone: 1-877-635-9545
Prior Authorization Fax: 1-844-712-8129

1230 US Highway 11
Gouverneur, NY 13642
Phone: 1-877-635-9545
Prior Authorization Fax: 1-844-712-8129

Stelara® Prior Authorization Request Form (Page 2 of 2)

Reauthorization:

If this is a reauthorization request, answer the following questions:

Is there documentation the patient has had a positive clinical response to Stelara therapy? ❑ **Yes** ❑ **No**

Is the patient receiving Stelara in combination with a biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]? ❑ **Yes** ❑ **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: This request may be denied unless all required information is received.

Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.

Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title): _____ **Date:** _____

PROACT INTERNAL USE ONLY:					
Clinical Review Decision					
	Approved, through				
	Denied (documentation attached, if necessary)				
Tracking:					
1st Attempt		2nd Attempt		Letter Mailed:	